Global Statistics

All countries
620,154,009
Confirmed
Updated on September 25, 2022 1:40 pm
All countries
598,732,161
Recovered
Updated on September 25, 2022 1:40 pm
All countries
6,540,178
Deaths
Updated on September 25, 2022 1:40 pm

Global Statistics

All countries
620,154,009
Confirmed
Updated on September 25, 2022 1:40 pm
All countries
598,732,161
Recovered
Updated on September 25, 2022 1:40 pm
All countries
6,540,178
Deaths
Updated on September 25, 2022 1:40 pm
- Advertisment -

How Effective Is The First Dose Of Pfizer Covid-19 Vaccine

Further Muddling Vaccine Rollout

Local kids react to getting first dose of Pfizer COVID-19 vaccine

Timothy C. Y. Chan, PhD, a professor of industrial engineering at the University of Toronto and the Canada research chair in Novel Optimization and Analytics in Health, tells Verywell that a single dose of mRNA vaccines is an idea worth exploring when supplies are limited or supply chains are interrupted.

Still, its not a one-size-fits-all approach and there are logistical issues to consider. A regimen that differs from the one laid out by the vaccine manufacturer could add a level of confusion or disorganization to vaccine efforts, he says.

It does add a bit of an additional challenge when we’re thinking about keeping track of who already has had one dose and making sure they come backto get the second one, he says. What if someone misses their appointment, and they come back a week later and say, Oh, I’d like my shot now.? You’d have to decide, do you give it to this person? Or do you give it to the person who’s getting their first shot?

Logistical issues aside, Raabe says a short delay between the recommended timing between the first and second dose of the Pfizer vaccine may not be cause for major concern, but pushing weeks or months out? Its too early to tell what effects that may have. We dont have good data for what happens when you significantly delay the second dose, she says.

Maximizing Uptake Of 2 Vaccine Doses

In a in the same journal, Stephen Evans, MSc, and Nicholas Jewell, PhD, both of the London School of Hygiene and Tropical Medicine, pointed out that as of Jun 19, coronavirus vaccines had prevented an estimated 7.2 million infections and 27,000 deaths in England and 279,000 deaths and 1.25 million hospitalizations in the United States as of the end of June.

Evans and Jewell said that although test-negativedesign studies such as the one by Public Health England can be subject to biases, the key results are encouraging and highlight the need for two doses in the prevention of infections caused by Delta.

“As the delta variant affects various countries, including the United States, the current imperative is to vaccinate as many people as possible, as quickly as possible,” they wrote. “Underserved and at-risk communities must not be neglected when implementing this strategy.”

Blood Products Human Immunoglobulin And Timing Of Immunization

NACI recommends that COVID-19 vaccines should not be given simultaneously with monoclonal antibodies or convalescent plasma.

To date, there is insufficient evidence on the receipt of both a COVID-19 vaccine and anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment or prevention. Therefore, timing of administration and potential interference between these two products are currently unknown. Administration of these products close together may result in decreased effectiveness of a COVID-19 vaccine and/or anti-SARS-CoV-2 monoclonal antibodies because the monoclonal antibodies have high affinity for the spike protein expressed by the vaccines, which could prevent the production of antibodies stimulated by the vaccine.

In the post-exposure setting, expert clinical opinion should be sought on a case-by-case basis when deciding whether anti-SARS-CoV-2 monoclonal antibodies would be appropriate to administer after receipt of COVID-19 vaccine, taking into consideration the risk of exposure and the risk of severe COVID-19 disease in the individual.

To date, there is also insufficient evidence on the receipt of both a COVID-19 vaccine and any monoclonal antibodies or convalescent plasma for treatment or prevention of non-COVID-19 disease. Therefore, timing of administration and potential interference between these two products are currently unknown and expert clinical opinion should be sought on a case-by-case basis.

You May Like: When Is It Safe To Be Around Someone With Covid

What This Means For You

If you’ve received a single dose of the Pfizer-BioNTech or Moderna vaccine, you likely already have some protection against the virus. But at this time, the U.S. government is not recommending receiving a single dose of either vaccine. Getting your second dose of the COVID-19 vaccine is imperative for achieving high immunity levels and protecting yourself.

If My Child Is About To Turn 12 Should I Wait

1 dose of Moderna, Pfizer vaccines effective against COVID ...

There is no major difference in the immune systems of an 11 and 12 year old.

The age cut-off was chosen based on the ages of the children in the vaccine trials. These age groupings were most likely designed to match the ages children are when they attend primary and high school.

If your 11 year old is about to turn 12, they should get the dose at 11 and not wait.

If they had the 10 microgram dose and turn 12 before their second dose is due, ATAGI says they may get a 30 microgram second dose when they are 12.

Read Also: Covid Test Cost Cvs

Severe Outcomes Due To Covid

Severe COVID-19 disease

Severe COVID-19 disease, defined as study participants who met the confirmed COVID-19 case definition and were assigned a severity score of â¥6 on the World Health Organization Clinical Progression Scale , was assessed as a secondary analysis of vaccine efficacy. Analysis included study participants who had been followed for â¥15 days since Dose 2, who were seronegative for SARS-CoV-2 at baseline, and received both doses of the SD/SD regimen. As of December 7, 2020, there were 6,085 study participants in the vaccine group and 6,073 participants in the control group. There was 1 case of severe COVID-19 disease identified in a study participant in the control group who received the control intervention within the 4-12-week dosing interval. This participant also required ICU admission and eventually died. An additional severe case occurred > 21 days after the first dose and â¤14 days after the second dose in a study participant in the control group.

Hospitalizations
Table 13 : Estimates of vaccine efficacy against hospitalization, by dosing interval

Time period of interest
Deaths

As of the updated data cut-off date of December 7, 2020, there has been a single death due to COVID-19 identified in a study participant in the control group.

Pfizers Vaccine Offers Strong Protection After First Dose

The Food and Drug Administrations first analysis of the clinical trial data also found that the coronavirus vaccine worked well regardless of a volunteers race, weight or age.

By Noah Weiland and Carl Zimmer

WASHINGTON The coronavirus vaccine made by Pfizer and BioNTech provides strong protection against Covid-19 within about 10 days of the first dose, according to documents published on Tuesday by the Food and Drug Administration before a meeting of its vaccine advisory group.

The finding is one of several significant new results featured in the briefing materials, which include more than 100 pages of data analyses from the agency and from Pfizer. Last month, Pfizer and BioNTech announced that their two-dose vaccine had an efficacy rate of 95 percent after two doses administered three weeks apart. The new analyses show that the protection starts kicking in far earlier.

Whats more, the vaccine worked well regardless of a volunteers race, weight or age. While the trial did not find any serious adverse events caused by the vaccine, many participants did experience aches, fevers and other side effects.

This is what an A+ report card looks like for a vaccine, said Akiko Iwasaki, an immunologist at Yale University.

On Thursday, F.D.A.s vaccine advisory panel will discuss these materials in advance of a vote on whether to recommend authorization of Pfizer and BioNTechs vaccine.

You May Like: Cost Of Rapid Test At Cvs

Recommendations On Authorized Available Covid

These recommendations apply only to COVID-19 vaccines currently authorized for use in Canada . In considering these recommendations and for the purposes of publicly funded program implementation, provinces and territories may consider local programmatic factors and local epidemiology .

  • NACI preferentially recommends that a complete series with an mRNA COVID-19 vaccine should be offered to individuals in the authorized age group without contraindications to the vaccine.

  • NACI recommends that a viral vector COVID-19 vaccine may be offered to individuals in the authorized age group without contraindications to the vaccine to initiate a series when other authorized COVID-19 vaccines are contraindicated or inaccessible. Informed consent should include discussion about the risk and symptoms of VITT, as well as the need to seek immediate medical care should symptoms develop.
  • Refer to Table 5 for a summary of evidence and factors for jurisdictions to consider when implementing COVID-19 immunization programs.

    Summary of evidence and rationale:

    mRNA COVID-19 vaccines

    Informed consent for mRNA COVID-19 vaccines should include information about very rare reports of myocarditis or pericarditis in the week following an mRNA vaccine

    AstraZeneca COVID-19 vaccine

  • In clinical trials, the majority of local and systemic adverse events with the AstraZeneca COVID-19 vaccine were mild and transient and did not differ by dose administered or age.
  • Immunosuppressed persons

    Appendix A: Clinical Trial Evidence Summary For Pfizer

    U.S. study: Pfizer, Moderna COVID-19 vaccines highly effective after first dose | ANC

    Study C4591001 is the pivotal Phase 1/2/3 trial for the Pfizer-BioNTech COVID-19 vaccine. Evidence on immunogenicity is available participants aged 12 to 15, 16 to 55, and 65 to 85. Evidence on the safety and efficacy of the vaccine is available for adolescents 12-15 years of age and adults 16 years of age and older. Studies did not include participants from long term care facilities. The Phase 2/3 portion of the trial involved approximately 46,000 study participants randomized to receive either the vaccine or placebo. The data presented below are for an interim analysis, therefore the time of follow-up is not consistent but was less than four months after the second dose for all participants.

    Evidence from the ongoing Phase 2/3 trial were published in December 2020 and May 2021 respectively, after NACI’s review of the evidence. Evidence from post-marketing surveillance and studies is found in the main body of this statement.

    You May Like: How Much Are Cvs Covid Tests

    Appendix B: Clinical Trial Evidence Summary For Moderna Covid

    Pivotal Phase 1, 2, and 3 trials are being conducted for the Moderna COVID-19 vaccine. Evidence on efficacy, immunogenicity, and safety is available for adults â¥18 years of age. Studies did not include participants from long term care facilities. The Phase 3 portion of the trial involved 30,413 study participants randomized to receive either the vaccine or placebo. The data presented below are for an interim analysis, therefore the time of follow-up is not consistent but was a median of two months after the second dose for all participants. Evidence from post-marketing surveillance and studies is found in the main body of this statement.

    Can My Child With Allergies Still Get The Vaccine

    Children who have had an allergic reaction to a substance called PEG which is a commonly used ingredient of other medications, hand sanitisers, cosmetics and bathroom products should talk to their GP before getting the vaccine.

    If your child has an allergic reaction after the first dose, talk to your GP before getting dose two.

    Children who are allergic to foods such as nuts, milk or eggs, or those who have asthma or hay fever, can safely receive the Pfizer vaccine.

    Recommended Reading: How Much Is Covid Test At Cvs

    Catching And Passing On Covid

    The Pfizer vaccine is effective at reducing the number of people who get COVID-19.

    Its harder to find out how well the vaccine stops people passing on the COVID-19 virus. Recent studies show that the Pfizer vaccine can reduce transmission of the virus. These studies looked at the number of people infected with COVID-19 after theyd been vaccinated and their close contacts.

    When Will Kids Under 5 Be Vaccinated

    Pfizer Covid vaccine 94% effective, study of 1.2m people ...

    Results from clinical trials in children under five years old are expected soon.

    Moderna is also trialling lower doses of its vaccine in children under five.

    Vaccinating 5-11 year-old Australian children is is an important next step in our ability to protect both ourselves and the community against COVID-19. The safety of the vaccines will be closely monitored as we roll them out in January and aim to give first doses before children go back to school.

    Also Check: How Much Is Covid Test At Cvs

    If The Gap Between Your Appointments Is Less Than 6 Weeks

    If you have already booked and the gap between your appointments is less than 6 weeks, you can keep the second appointment or choose to change it.

    The important thing is to get 2 doses of the vaccine to be fully vaccinated.

    To cancel or modify your booking you can:

    • call the COVID Vaccination Healthline on .

    How Well The Vaccine Works

    • Based on evidence from clinical trials in people 16 years and older, the Pfizer-BioNTech vaccine was 95% effective at preventing laboratory-confirmed infection with the virus that causes COVID-19 in people who received two doses and had no evidence of being previously infected.
    • In clinical trials, the Pfizer-BioNTech vaccine was also highly effective at preventing laboratory-confirmed COVID-19 infection in adolescents 1215 years old, and the immune response in people 1215 years old was at least as strong as the immune response in people 1625 years old.
    • The vaccine was also highly effective in clinical trials at preventing COVID-19 among people of diverse age, sex, race, and ethnicity categories and among people with underlying medical conditions.
    • Evidence shows mRNA COVID-19 vaccines offer similar protection in real-world conditions as they have in clinical trial settingsreducing the risk of COVID-19, including severe illness by 90% or more, among people who are fully vaccinated.
    • CDC will continue to provide updates as we learn more.

    You May Like: How Much Does Cvs Charge For Covid Test

    Getting Your Second Dose Of The Covid Vaccine Here’s What You Should Know

    Unlike the Pfizer and Moderna shots, the J& J vaccine uses a cold virus, called an adenovirus, to carry the spike gene into the body. J& J uses a human adenovirus to create its vaccine while a similar vaccine not yet approved in the U.S., AstraZeneca, uses a chimpanzee version.

    J& Js shot uses a cold virus like a Trojan horse to carry the spike gene into the body, where cells make harmless copies of the protein to prime the immune system in case the real virus comes along. Its the same technology the company used in making an Ebola vaccine.

    Pfizer Vaccine Effectiveness Diminishes Against Infection Not Severe Disease

    Idaho families line up to get first dose of children’s Pfizer COVID-19 vaccine

    Disclosures: We were unable to process your request. Please try again later. If you continue to have this issue please contact .

    The effectiveness of the Pfizer-BioNTech vaccine against any SARS-CoV-2 infection was about 20% among patients in Qatar 5 to 7 months after administration of the second dose, a study in The New England Journal of Medicine showed.

    However, vaccine effectiveness against COVID-19-related hospitalization or death persisted with hardly any waning for 6 months after the second dose, researchers wrote.

    In a second study also published in The New England Journal of Medicine, data from vaccine recipients in Israel revealed substantial declines in neutralizing antibody titers, particularly among certain populations, 6 months after receipt of the second Pfizer-BioNTech dose.

    Vaccine efficacy rates

    In the first study, researchers conducted a matched test-negative, case-control trial to analyze vaccine efficacy in 907,763 Qatar residents of various national origins who received two Pfizer-BioNTech vaccine doses.

    We were unable to use a cohort study design owing to depletion of the unvaccinated cohorts by the high vaccine coverage,Hiam Chemaitelly, MSc, a senior epidemiologist supervisor at Weill Cornell Medical College in Qatar, and colleagues wrote.

    Neutralizing antibody titers

    References

    You May Like: Did Hank Aaron Die From Vaccine

    Pfizers Vaccine Protection May Wane After 2 Months

    Oct. 8, 2021 — The protection from Pfizerâs COVID-19 vaccine may begin to wane against infection after 2 months, but it still prevents hospitalization and death for at least 6 months, according to two new studies published Wednesday in TheNew England Journal of Medicine.

    The new findings support what Pfizer, the CDC, and top health officials have said in recent weeks: Initial protection against getting the coronavirus itself may drop over time, but people who get the vaccine avoid the worst effects of severe disease.

    In the first study, researchers in Qatar estimated vaccine efficacy against COVID-19 infection and severe, critical, or fatal cases between Jan. 1 and Sept. 5. They based the report on infections among 900,000 vaccinated people in Qatar.

    After the first Pfizer dose, protection against infection was ânegligibleâ for the first 2 weeks but jumped to about 37% in the third week. Protection then reached a peak of about 78% in the first month after the second dose.

    Efficacy fell gradually after that, with the decline speeding up after the fourth month. For some people who got the vaccine, protection dropped as low as 20% between 5 and 7 months after the second dose.

    âThese findings suggest that a large proportion of the vaccinated population could lose its protection against infection in the coming months, perhaps increasing the potential for new epidemic waves,â the researchers wrote.

    Pfizer And Biontech Announced The Results Of Testing That Shows Boosters Neutralize The Omicron Variant Of The Coronavirus

    GEORGIA Getting a booster is the best way to protect against the omicron variant of the coronavirus, medical professionals say.

    On Wednesday, Pfizer officials released the results of an initial lab study showing that its vaccine neutralizes the omicron variant after three doses.

    “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” Pfizer CEO Albert Bourla said Wednesday in a statement. “Ensuring as many people as possible are fully vaccinated with the first two-dose series and a booster remains the best course of action to prevent the spread of COVID-19.”

    Also Check: How Much Is Covid Test At Cvs

    - Advertisment -

    Hot Topics

    - Advertisment -

    Related Articles